Skip to main content
OpenTrials
Completed

NCT Number: NCT01526395

Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital

In developing countries, electroconvulsive therapy (ECT) is typically delivered without the use of an anesthetic prior to the treatment, known as unmodified ECT. This interventional study aims to decrease the practice of unmodified ECT at Chhatrapati Shahuji Maharaj Medical University, U.P. & G.M. & Associated Hospitals (C.S.M) by administering a low dose anesthetic (propofol) prior to ECT delivery. In so doing, the investigators hope to facilitate the transition from unmodified to modified ECT without incurring excessive costs to the center. It is hypothesized that ECT patients will opt for modified treatment, that adverse effects will be minimal, and that costs will not rise prohibitively.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chhatrapati Shahuji Maharaj Medical University, U.P. & G.M. & Associated Hospitals

Lucknow, Uttar Pradesh, 226003, India

About this study

Patients that are currently receiving unmodified ECT at C.S.M Hospital will be eligible for the first phase of the study in which only data is collected. Three months after study start, patients who are to receive ECT for a psychiatric disorder will be eligible to participate in the intervention (introduction of propofol at a low dose prior to ECT). Data collection will include information such as demographics, ratings scales, seizure length, anxiety level, adverse events, and number of treatments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects are any psychiatric patients at C.S.M. for whom ECT is recommended by their doctor, whether or not they actually receive ECT.
  • Subjects must also have an American Society for Anesthesiologists (ASA) rating score of 1 (completely healthy) or 2 (mild systemic disease) with stable symptoms and laboratory values.
  • Subjects must be between the ages of 18 to 65 years old and be able to give informed consent.

Exclusion criteria

  • Patients who speak neither English nor Hindi.
  • History of or anatomical evidence for a difficult airway being a short mandible, micrognathia, large tongue or large goiter, arthritis of the jaw or neck, or enlarged tonsils. For this reason we will also exclude patients with a BMI > 28.
  • Respiratory tract disease including asthma, respiratory infection, chest wall disease, chronic obstructive pulmonary disease, obstructive sleep apnea, or other disorder which might compromise the airway. Patients who smoke 15 or more cigarettes per day will be excluded unless abstinent for at least 10 days, to reduce the risk of respiratory complications.
  • Patients who receive modified ECT during the first phase of the study.
  • Pregnant women or women who are breastfeeding.
  • Hypersensitivity to propofol or any of its components.
  • Patients who are hemodynamically unstable or who have impaired cardiac function.
  • BMI < 18.
  • Patients with a history of epilepsy

Treatment and study plan

Propofol

Drug

The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be "amnestic," meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week.

Primary outcomes

  1. Percentage of patients receiving ECT who agree to the modified form of treatment after it is offered.

    Time frame: 6 months

Secondary outcomes

  1. Rate at which ECT is offered and refused.

    Time frame: 6 months

  2. Change in patient anxiety measured by the state portion of the State-Trait Anxiety Inventory.

    Time frame: Baseline and completion of ECT treatments or up to 6 months, whichever comes first

  3. Inpatient length of stay calculated from onset of ECT administration.

    Time frame: 6 months

  4. Number of ECTs required to complete a course of treatment

    Time frame: 6 months

  5. Changes in scales used to assess severity of symptoms. The investigators will record changes in the Hamilton Depression Rating Scale, the Young Mania Rating Scale, the Brief Psychiatric Rating Scale and the Clinical Global Impression Severity scale.

    Time frame: Baseline and completion of ECT treatments or up to 6 months, whichever comes first

  6. Cognitive changes, monitored by the Mini Mental State Examination (MMSE)

    Time frame: Baseline and completion of ECT treatments or up to 6 months, whichever comes first

  7. Monitoring of adverse effects such the occurence of emergent delirium, headaches, muscle aches, nausea and vomiting, and fractures and dislocations.

    Time frame: Baseline and completion of ECT treatments or up to 6 months, whichever comes first

  8. Monitoring of delirium using the test with the Confusion Assessment Method for the ICU (CAM-ICU).

    Time frame: Baseline and completion of ECT treatments or up to 6 months, whichever comes first

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • Chhatrapati Shahuji Maharaj Medical University
  • Johns Hopkins Bloomberg School of Public Health

Registry information

Official study title

Decreasing the Use of Unmodified ECT in an Indian Hospital

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Feb 3, 2012
Registry last updated
Apr 4, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.